Nerisona (Diflucortolone Valerate)

Diflucortolone valerate is a topical corticosteroid used to manage inflammatory skin conditions.

• Eczema: reduces redness, swelling and itching associated with atopic dermatitis.
• Psoriasis: diminishes plaque formation and scaling in plaque psoriasis.
• Dermatitis: alleviates irritation and inflammation in contact or seborrheic dermatitis.
• Other inflammatory skin disorders: provides symptomatic relief in various chronic inflammatory dermatoses.

• Diflucortolone valerate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses pro‑inflammatory cytokine production, inhibits leukocyte migration, and reduces fibroblast proliferation, resulting in anti‑inflammatory, immunosuppressive and antiproliferative effects in the skin.

Topical diflucortolone valerate may cause local adverse reactions, most of which are mild and reversible.

Common Side Effects

• Burning or stinging at the application site.
• Pruritus or mild itching.
• Dryness or flaking of the skin.
• Erythema or mild redness.
• Folliculitis or small pustules.
• Telangiectasia (visible small blood vessels).

Serious or Rare Side Effects

• Skin atrophy or thinning with prolonged use.
• Striae (stretch marks) formation.
• Secondary bacterial, fungal or viral skin infections.
• Hypersensitivity reactions such as contact dermatitis.
• Systemic absorption leading to adrenal suppression (rare).
• Delayed wound healing.

Before using diflucortolone valerate, consider the following safety measures.

• Avoid prolonged use on large surface areas: limit duration to reduce risk of systemic effects.
• Do not apply to infected or ulcerated skin: may worsen infection.
• Use with caution in children: higher per‑kg absorption can increase adverse effects.
• Discontinue if severe irritation or allergic reaction occurs: seek medical advice.
• Avoid occlusive dressings unless directed: can enhance drug penetration.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Diflucortolone valerate can interact with other agents that affect skin integrity or systemic corticosteroid exposure.

Major Interactions (Avoid)

• Systemic corticosteroids: concurrent use may increase risk of systemic glucocorticoid effects.
• Potent immunosuppressants (e.g., tacrolimus, cyclosporine): may heighten infection risk.
• Antifungal or antibacterial topical agents on the same area: can alter absorption and increase irritation.

Moderate Interactions (Monitor Closely)

• Skin‑lightening agents (hydroquinone): may increase irritation.
• Retinoids (topical or oral): potential for additive skin irritation.
• Non‑steroidal anti‑inflammatory drugs (topical): monitor for enhanced local reactions.